Systematic Review: Patterns of Proton Pump Inhibitor Use and Adherence in Gastroesophageal Reflux Disease

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 2, 2012, Pages 109-116

  Hungin, Pali A S ^a   Hill, Catherine ^b   Molloy Bland, Michael ^b   Raghunath, Anan ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

Author keywords

Adherence; Concomitant Medication; Dosing Frequency; Medication Possession Ratio; Reflux Symptoms

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGE; BARRETT ESOPHAGUS; DEMOGRAPHY; DISEASE SEVERITY; DRUG USE; GASTROESOPHAGEAL REFLUX; HUMAN; PATIENT COMPLIANCE; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW;

GASTROESOPHAGEAL REFLUX; HUMANS; MEDICATION ADHERENCE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84856062179     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.07.008     Document Type: Review

References (36)

1. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920.
2. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
3. Wong B.C., Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006, 4:398-407.
4. Dent J. Review article: from 1906 to 2006-a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006, 24:1269-1281.
5. van Pinxteren B., Numans M.E., Bonis P.A., et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004, CD002095.
6. Donnellan C., Sharma N., Preston C., et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005, 4. CD003245.
7. Eggleston A., Katelaris P.H., Nandurkar S., et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care-prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009, 29:967-978.
8. Hungin A.P., Gunn S.D., Bate C.M., et al. A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bd in the relief of symptomatic gastro-esophageal reflux disease in general practice. British Journal of Clinical Research 1993, 4:73-88.
9. Kaplan-Machlis B., Spiegler G.E., Zodet M.W., et al. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000, 9:624-630.
10. Talley N.J., Moore M.G., Sprogis A., et al. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 2002, 177:423-427.
11. Crawley J.A., Schmitt C.M. How satisfied are chronic heartburn sufferers with their prescription medications?. Results of the patient unmet needs survey. J Clin Outcomes Manage 2000, 7:29-34.
12. Jones R., Liker H.R., Ducrotté P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007, 61:1301-1307.
13. Raghunath A.S., Hungin A.P., Mason J., et al. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009, 29:431-439.
14. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
15. Augood C., MacLennan S., Gilbert R., et al. Cisapride treatment for gastro-oesophageal reflux in children (Cochrane Review). Cochrane Database Syst Rev 2003, CD002300.
16. Van Soest E.M., Siersema P.D., Dieleman J.P., et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006, 24:377-385.
17. Gosselin A., Luo R., Lohoues H., et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009, 12:34-39.
18. El-Serag H.B., Fitzgerald S., Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol 2009, 104:2161-2167.
19. Hall J., Dodd S., Durkin M., et al. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care 2002, 11:14-18.
20. Monane M., Bohn R.L., Gurwitz J.H., et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997, 10:697-704.
21. Ward A., Ishak K., Proskorovsky I., et al. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006, 28:1912-1921.
22. Thiebaud P., Patel B.V., Nichol M.B., et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005, 11:670-674.
23. Hoogendoorn R.J., Groeneveld L., Kwee J.A. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study. Clin Drug Invest 2009, 29:803-810.
24. Jones R., Armstrong D., Malfertheiner P., et al. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs?. A survey-based study. Curr Med Res Opin 2006, 22:657-662.
25. Robinson M., Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharmacol Ther J 2002, 27:202-206.
26. Hungin A.P., Rubin G., O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999, 49:463-464.
27. Kamolz T. Analysis of medical compliance in gastro-oesophageal reflux disease patients referred to pre-surgical examination. Dig Liver Dis 2002, 34:183-189.
28. Chey W.D., Mody R.R., Wu E.Q., et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin 2009, 25:1869-1878.
29. Bretagne J.F., Honnorat C., Richard-Molard B., et al. Management of gastroesophageal reflux disease by primary care physicians and gastroenterologists: a prospective study of patients' records. Gastroenterol Clin Biol 2008, 32:995-1000.
30. Gunaratnam N.T., Jessup T.P., Inadomi J., et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006, 23:1473-1477.
31. Ruigómez A., Lundborg P., Johansson S., et al. Partial response to proton pump inhibitor treatment in children and adolescents with gastroesophageal reflux disease in UK primary care. Gastroenterology 2010, 138(Suppl 1):S-650.
32. Grime J., Pollock K., Blenkinsopp A. Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001, 51:703-711.
33. Shaker R., Castell D.O., Schoenfeld P.S., et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98:1487-1493.
34. Boeckxstaens G.E., Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010, 32:334-343.
35. Fass R., Shapiro M., Dekel R., et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 2005, 22:79-94.
36. Hershcovici T., Fass R. Nonerosive reflux disease (NERD)-an update. Neurogastroenterol Motil 2010, 16:8-21.